Hunan Warrant Pharmaceutical Co.Ltd(688799) board of directors
Special report on the deposit and use of raised funds in 2021
According to the self regulatory guidelines No. 1 – standardized operation of companies listed on the science and Innovation Board of Shanghai Stock Exchange (SZF [2022] No. 14) and relevant format guidelines issued by Shanghai Stock Exchange, the following special report is made on the deposit and use of raised funds of Hunan Warrant Pharmaceutical Co.Ltd(688799) (hereinafter referred to as “the company” or “the company”) in 2021:
1、 Basic information of raised funds
(I) actual amount of raised funds and time of fund arrival
According to the reply on Approving the registration of Hunan Warrant Pharmaceutical Co.Ltd(688799) initial public offering of shares (zjxk [2021] No. 1966) issued by China Securities Regulatory Commission, the company’s lead underwriter Western Securities Co.Ltd(002673) adopts the balance underwriting method to publicly issue 23.5 million RMB ordinary shares (A shares) to the public at an issue price of 30.82 yuan per share, raising a total of 724.27 million yuan, The capital raised by the underwriter on the date of and the supervision account of the underwriter is 6.701 million yuan, including the value-added tax of 6.701 million yuan. In addition, after deducting the online issuance fee, prospectus printing fee, reporting accountant fee, lawyer fee, evaluation fee and other new external expenses directly related to the issuance of equity securities of 212092 million yuan (excluding value-added tax), plus the corresponding value-added tax of 2.8444 million yuan for the underwriting and recommendation fee of this issuance, the net capital raised by the company is 6556548 million yuan. The availability of the above raised funds has been verified by Tianjian Certified Public Accountants (special general partnership), who issued the capital verification report (Tianjian Yan [2021] No. 2-19).
(II) use and balance of raised funds
Monetary unit: RMB 10000
Item No. amount
Net amount of raised funds a 6556548
Project investment B1 575729 accumulated amount as of the beginning of the period
Net interest income B2
Project investment C1 939942 current amount
Net interest income C2 608.38
Accumulated amount by the end of the period: project investment D1 = B1 + C11515671
Item No. amount
Net interest income D2 = B2 + C2 608.38
Balance of fund raised e = a-d1 + D25101715
Actual balance of raised funds f 5123980
Difference g = E-F -222.66 [note]
[note] on August 4, 2021, the company held the 9th meeting of the 2nd board of directors and the 8th meeting of the 2nd board of supervisors, deliberated and adopted the proposal on using self owned funds and bank acceptance bills to pay the funds required for the raised investment projects and replacing them with the raised funds in equal amount. It is agreed that the company and its subsidiaries will use self owned funds and bank acceptance bills to pay part of the funds required for the raised investment projects during the implementation of the raised investment projects, After that, it shall be replaced with the raised funds in equal amount on a regular basis and transferred from the special account of the raised funds to the general account of the company. This part of the equal replacement funds shall be regarded as the use funds of the raised investment project; The above difference is that the company has used its own funds to pay the amount that has not been replaced and transferred to the company’s general account in 2021.
2、 Management of raised funds
(I) management of raised funds
In order to standardize the management and use of raised funds, improve the efficiency and efficiency of fund use, and protect the rights and interests of investors, In accordance with the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the Listing Rules of Kechuang board of Shanghai Stock Exchange (revised in December 2020) (SZF [2020] No. 101) and the self regulatory guidelines for Kechuang board listed companies of Shanghai Stock Exchange No. 1 – standardized operation (SZF [2022] No. 14) and other relevant laws, regulations and normative documents, In combination with the actual situation of the company, the management measures for Hunan Warrant Pharmaceutical Co.Ltd(688799) raised funds (hereinafter referred to as the management measures) are formulated. According to the management measures, the company has implemented a special account for the raised funds, established a special account for the raised funds in the bank, and signed the tripartite supervision agreement for the raised funds with China Minsheng Banking Corp.Ltd(600016) Changsha branch and Bank Of Changsha Co.Ltd(601577) Liuyang sub branch together with the sponsor Western Securities Co.Ltd(002673) on July 6, 2021, clarifying the rights and obligations of all parties. On July 6, 2021, the company and its wholly-owned subsidiary, Hunan Warner pharmaceutical Chiral Pharmaceutical Co., Ltd., together with the sponsor Western Securities Co.Ltd(002673) and China Minsheng Banking Corp.Ltd(600016) Changsha branch and China Merchants Bank Co.Ltd(600036) Changsha branch respectively signed the four party supervision agreement on raising funds, clarifying the rights and obligations of all parties. On August 10, 2021, the company and its wholly-owned subsidiary, Hunan Warner pharmaceutical Chiral Pharmaceutical Co., Ltd., together with the sponsor Western Securities Co.Ltd(002673) and Bank Of Changsha Co.Ltd(601577) Liuyang sub branch, signed the four party supervision agreement on raising funds, clarifying the rights and obligations of all parties.
On July 6, 2021, the company and its wholly-owned subsidiary, Hunan Warner Pharmaceutical Co., Ltd., together with the sponsor Western Securities Co.Ltd(002673) and Bank Of China Limited(601988) Changsha Xingsha sub branch respectively signed the four party supervision agreement on raising funds, clarifying the rights and obligations of all parties. There is no significant difference between the tripartite regulatory agreement and the model tripartite regulatory agreement of Shanghai Stock Exchange, and the company has strictly complied with the raised funds.
(II) storage of raised funds in special account
As of December 31, 2021, the company has 6 special accounts for raised funds, 10 large certificates of deposit accounts and 6 structured deposit accounts. The deposits of raised funds are as follows:
Monetary unit: RMB
Remarks on the balance of raised funds in the account number of the deposit bank
6330869363212267929 current account
6331044711635464406 current account
7086317671000000000 certificate of deposit
7086322961000000000 certificate of deposit
7081974161000000000 certificate of deposit
China China Minsheng Banking Corp.Ltd(600016) shares have 7082590341000000000 certificate of deposit
Limited company Changsha branch 70825841000000000 certificate of deposit
70826 Skyworth Digital Co.Ltd(000810) 00000000 certificate of deposit
7082597531000000000 certificate of deposit
7082606021000000000 certificate of deposit
7082596651000000000 certificate of deposit
7082594131000000000 certificate of deposit
80 Shenzhen Guohua Network Security Technology Co.Ltd(000004) 3391 Shenzhen Nanshan Power Co.Ltd(000037) 88514870 current account
8 Ping An Bank Co.Ltd(000001) 89084 China Vanke Co.Ltd(000002) 156676879 current account
Bank Of Changsha Co.Ltd(601577) Co., Ltd. 10300000000 structured deposit
Si Liuyang sub branch 10300000000 structured deposit
1100000000 structured deposit
1100000000 structured deposit
China Merchants Bank Co.Ltd(600036) Co., Ltd. 7319087219102075264400898 current account
Division Changsha Branch
596377210987182479799 current
Bank Of China Limited(601988) Co., Ltd. 5963778413903700000000 structured deposit
Changsha Xingsha sub branch
5950778487563500000000 structured deposit
Total – 51239804781
3、 Actual use of raised funds this year
(I) comparison table of use of raised funds
See Annex 1 of this report for the comparison table of the use of raised funds.
(II) description of abnormal investment of the project
There are no abnormalities in the investment projects of the company with raised funds.
(III) description of the situation that the benefits of the investment project with raised funds cannot be calculated separately
The company does not have the situation that the benefits of investment projects with raised funds cannot be calculated separately.
4、 Change the use of funds of raised investment projects
This year, the company did not change the investment projects of raised funds.
5、 Problems in the use and disclosure of raised funds
This year, there were no major problems in the use and disclosure of the raised funds of the company.
6、 Other
On August 4, 2021, the company held the ninth meeting of the second board of directors and the eighth meeting of the second board of supervisors, deliberated and approved the proposal on increasing the implementation subject of some fund-raising investment projects, and agreed to add a wholly-owned subsidiary of the company, Hunan Warner pharmaceutical chiral drugs Co., Ltd. (hereinafter referred to as chiral drugs company) as the implementation subject of the fund-raising investment project “drug R & D project”, And transfer the raised funds required for the implementation of the raised investment project through internal exchanges; After adjustment, the implementation subject of the company’s fund-raising project “drug R & D project” is the company and chiral drug company.
7、 Concluding opinions of the assurance report issued by the accounting firm on the deposit and use of the company’s annual raised funds
Tianjian Certified Public Accountants (special general partnership) believes that the special report on the annual storage and use of raised funds prepared by the board of directors of the company in 2021 complies with the provisions of self regulatory guidelines No. 1 – standardized operation of companies listed on the science and Innovation Board of Shanghai Stock Exchange (SZF [2022] No. 14) and relevant format guidelines, and truthfully reflects the actual storage and use of raised funds of the company in 2021.
8、 Sponsor’s response to
